

ICMJE DISCLOSURE FORM

Date: Oct. 19th, 2021

Your Name: Lili Wang

Manuscript Title: Benefits from standalone Durvalumab treatment in an elderly patient with advanced prostatic sarcoma: a case report

Manuscript number (if known): TAU-21-125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>Lili Wang</u> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>Lili Wang</u> None	
3	Royalties or licenses	<u>Lili Wang</u> None	
4	Consulting fees	<u>Lili Wang</u> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u> </u> Lili Wang <u> </u> None	
6	Payment for expert testimony	<u> </u> Lili Wang <u> </u> None	
7	Support for attending meetings and/or travel	<u> </u> Lili Wang <u> </u> None	
8	Patents planned, issued or pending	<u> </u> Lili Wang <u> </u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> </u> Lili Wang <u> </u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> </u> Lili Wang <u> </u> None	
11	Stock or stock options	<u> </u> Lili Wang <u> </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> </u> Lili Wang <u> </u> None	
13	Other financial or non-financial interests	<u> </u> Lili Wang <u> </u> None	

Please summarize the above conflict of interest in the following box:

None.

Please place an "X" next to the following statement to indicate your agreement:

 X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Oct. 19th, 2021

Your Name: Lei Wang

Manuscript Title: Benefits from standalone Durvalumab treatment in an elderly patient with advanced prostatic sarcoma: a case report

Manuscript number (if known): TAU-21-125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>Lei Wang</u> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>Lei Wang</u> None	
3	Royalties or licenses	<u>Lei Wang</u> None	
4	Consulting fees	<u>Lei Wang</u> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u>Lei Wang</u> <u>None</u>	
6	Payment for expert testimony	<u>Lei Wang</u> <u>None</u>	
7	Support for attending meetings and/or travel	<u>Lei Wang</u> <u>None</u>	
8	Patents planned, issued or pending	<u>Lei Wang</u> <u>None</u>	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>Lei Wang</u> <u>None</u>	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>Lei Wang</u> <u>None</u>	
11	Stock or stock options	<u>Lei Wang</u> <u>None</u>	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>Lei Wang</u> <u>None</u>	
13	Other financial or non-financial interests	<u>Lei Wang</u> <u>None</u>	

Please summarize the above conflict of interest in the following box:

None.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Oct. 19th, 2021

Your Name: Dingkun Hou

Manuscript Title: Benefits from standalone Durvalumab treatment in an elderly patient with advanced prostatic sarcoma: a case report

Manuscript number (if known): TAU-21-125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>Dingkun Hou</u> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>Dingkun Hou</u> None	
3	Royalties or licenses	<u>Dingkun Hou</u> None	
4	Consulting fees	<u>Dingkun Hou</u> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u> </u> <u>Dingkun Hou</u> <u> </u> None	
6	Payment for expert testimony	<u> </u> <u>Dingkun Hou</u> <u> </u> None	
7	Support for attending meetings and/or travel	<u> </u> <u>Dingkun Hou</u> <u> </u> None	
8	Patents planned, issued or pending	<u> </u> <u>Dingkun Hou</u> <u> </u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> </u> <u>Dingkun Hou</u> <u> </u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> </u> <u>Dingkun Hou</u> <u> </u> None	
11	Stock or stock options	<u> </u> <u>Dingkun Hou</u> <u> </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> </u> <u>Dingkun Hou</u> <u> </u> None	
13	Other financial or non-financial interests	<u> </u> <u>Dingkun Hou</u> <u> </u> None	

Please summarize the above conflict of interest in the following box:

None.

Please place an “X” next to the following statement to indicate your agreement:

 X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Oct. 19th, 2021

Your Name: Shiqiang Dong

Manuscript Title: Benefits from standalone Durvalumab treatment in an elderly patient with advanced prostatic sarcoma: a case report

Manuscript number (if known): TAU-21-125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>Shiqiang Dong</u> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>Shiqiang Dong</u> None	
3	Royalties or licenses	<u>Shiqiang Dong</u> None	
4	Consulting fees	<u>Shiqiang Dong</u> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u>Shiqiang Dong</u> <u>None</u>	
6	Payment for expert testimony	<u>Shiqiang Dong</u> <u>None</u>	
7	Support for attending meetings and/or travel	<u>Shiqiang Dong</u> <u>None</u>	
8	Patents planned, issued or pending	<u>Shiqiang Dong</u> <u>None</u>	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>Shiqiang Dong</u> <u>None</u>	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>Shiqiang Dong</u> <u>None</u>	
11	Stock or stock options	<u>Shiqiang Dong</u> <u>None</u>	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>Shiqiang Dong</u> <u>None</u>	
13	Other financial or non-financial interests	<u>Shiqiang Dong</u> <u>None</u>	

Please summarize the above conflict of interest in the following box:

None.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Oct. 19th, 2021

Your Name: Aixiang Wang

Manuscript Title: Benefits from standalone Durvalumab treatment in an elderly patient with advanced prostatic sarcoma: a case report

Manuscript number (if known): TAU-21-125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>Aixiang Wang</u> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>Aixiang Wang</u> None	
3	Royalties or licenses	<u>Aixiang Wang</u> None	
4	Consulting fees	<u>Aixiang Wang</u> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u> Aixiang Wang </u> None	
6	Payment for expert testimony	<u> Aixiang Wang </u> None	
7	Support for attending meetings and/or travel	<u> Aixiang Wang </u> None	
8	Patents planned, issued or pending	<u> Aixiang Wang </u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> Aixiang Wang </u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> Aixiang Wang </u> None	
11	Stock or stock options	<u> Aixiang Wang </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> Aixiang Wang </u> None	
13	Other financial or non-financial interests	<u> Aixiang Wang </u> None	

Please summarize the above conflict of interest in the following box:

None.

Please place an "X" next to the following statement to indicate your agreement:

 X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Oct. 19th, 2021

Your Name: Haitao Wang

Manuscript Title: Benefits from standalone Durvalumab treatment in an elderly patient with advanced prostatic sarcoma: a case report

Manuscript number (if known): TAU-21-125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>Haitao Wang</u> _ None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>Haitao Wang</u> _ None	
3	Royalties or licenses	<u>Haitao Wang</u> _ None	
4	Consulting fees	<u>Haitao Wang</u> _ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u>Haitao Wang</u> <u>None</u>	
6	Payment for expert testimony	<u>Haitao Wang</u> <u>None</u>	
7	Support for attending meetings and/or travel	<u>Haitao Wang</u> <u>None</u>	
8	Patents planned, issued or pending	<u>Haitao Wang</u> <u>None</u>	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>Haitao Wang</u> <u>None</u>	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>Haitao Wang</u> <u>None</u>	
11	Stock or stock options	<u>Haitao Wang</u> <u>None</u>	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>Haitao Wang</u> <u>None</u>	
13	Other financial or non-financial interests	<u>Haitao Wang</u> <u>None</u>	

Please summarize the above conflict of interest in the following box:

None.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.